Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Styphnolobium japonicum flower bud is a botanical ingredient derived from the *Styphnolobium japonicum* tree, also known as the Japanese pagoda tree or Chinese scholar tree, native to China. It is a fundamental herb in traditional Chinese medicine (TCM) and is also marketed as a dietary supplement. The primary active constituents are flavonoids, including rutin, quercetin, sophoricoside, genistein, and kaempferol. Its pharmacological activities include antioxidant, anti-inflammatory, hemostatic, and vascular-protective effects. It is traditionally used to treat a variety of conditions such as hemorrhoids, various bleeding disorders, hypertension, and inflammation. Modern research also explores its potential in supporting cardiovascular health, managing menopausal symptoms, and addressing conditions like diabetes and osteoporosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Styphnolobium japonicum flower bud.